Plough­ing through a crowd­ed PD-(L)1 mar­ket, BeiGene loads up on promis­ing lung can­cer da­ta

BeiGene’s en­try to the PD-1 mar­ket — as the fourth do­mes­tic drug­mak­er to score ap­proval in Chi­na, lag­ging months be­hind multi­na­tion­al play­ers — might have been un­re­mark­able. But the fol­low-up act is where it plans to shine.

Three months af­ter post­ing pos­i­tive top-line pro­gres­sion-free sur­vival re­sults for their piv­otal Chi­nese study with tislelizum­ab and chemo for front­line squa­mous non-small cell lung can­cer, BeiGene said the PD-1 an­ti­body hit the same mark for non-squa­mous cas­es of NSCLC. In both tri­als, the drug was paired with chemother­a­py and the reg­i­men was com­pared to chemo alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER